Plenary Session III

Session Type: ACR Plenary Sessions
Tuesday, November 8, 2011: 11:00 AM-12:30 PM
W375b (McCormick Place West)
SessionSelect
Moderators: Carol A. Langford, MD, MHS, Cleveland Clinic and Richard Furie, MD, North Shore-LIJ Health System
Papers:
11:00 AM
JAK2 Mediates the Stimulatory Effects ofáTransformingáGrowtháFactor betaáon Fibroblast Activation and Tissue Fibrosis
Clara Dees1, Michal Tomcik2, Katrin Palumbo1, Alfiya Akhmetshina3, Angelika Horn1, Pawel Zerr1, Oliver Distler4, Georg Schett1 and Jorg HW Distler1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4University Hospital Zurich, Zurich, Switzerland
11:15 AM
RNAi Mediated Silencing of the Autoantigen hnRNP-A2 Dcreases Inflammatory Arthritis by Inhibiting Activation of Cells of the Mononuclear Phagocytic System
Sonja Herman1, Jessy Presumey2, Juergen Pfatschbacher1, Wim B. Vandenberg3, Florence Apparailley2 and Gunter Steiner1, 1Medical University of Vienna, Vienna, Austria, 2H˘pital Saint Eloi, Montpellier, France, 3Radboud University Nijmegen Med Center, Nijmegen, Netherlands
11:30 AM
A Functional IRF5 Variant Predicts Prognosis in Patients with Systemic Sclerosis
Roozbeh Sharif1, Maureen D. Mayes1, Filemon K. Tan1, Olga Gorlova2, Laura K. Hummers3, Ami A. Shah3, Daniel E. Furst4, Dinesh Khanna5, Javier Martin6, Lara Bossini-Castillo7, Emilio B. Gonzalez8, Hilda T. Draeger9, Jun Ying10, Sandeep K. Agarwal1, Frank C. Arnett1, Fredrick M. Wigley3 and Shervin Assassi1, 1University of Texas Health Science Center at Houston, Houston, TX, 2University of Texas M.D. Anderson Cancer Center, Houston, TX, 3Johns Hopkins University, Baltimore, MD, 4UCLA Medical School, Los Angeles, CA, 5University of Michigan, Ann Arbor, MI, 6Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 7Consejo Superior de Investigaciones CientÝficas (CSIC), Armilla (Granada), Spain, 8University of Texas Medical Branch, Galveston, TX, 9Univ of TX Health Sci Ctr, San Antonio, TX, 10University of Texas M. D. Anderson Cancer Center, Houston, TX
11:45 AM
Feasibility, Safety and Clinical Effects of a Single Intradermal Administration of Autologous Tolerising Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis
Ranjeny Thomas, Shayna Street, Nishta Ramnoruth, Helen Pahau, Soi Law, Marion Brunck, Claire Hyde, Brendan O'Sullivan, Christelle Capini, Ai Tran, Jennifer Ng and Sanjoy Paul, Univ of Queensland, Brisbane, Australia
12:00 PM
Genome-Wide Analysis of Imputed Genotypes Identifies Chemokine Receptor-1 (CCR1) As a Novel Candidate Risk Locus in Behšet's Disease
Yohei Kirino1, George Bertsias1, Michael J. Ombrello1, Duran Ustek2, Colleen Satorius1, Julie Le1, Nobuhisa Mizuki3, Yoshiaki Ishigatsubo3, Emire Seyahi4, F. Sevgi Sacli4, Ahmet Gul5, Daniel L. Kastner1 and Elaine Remmers1, 1National Human Genome Research Institute, National Institute of Health, Bethesda, MD, 2Istanbul University, Istanbul, Turkey, 3Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey, 5Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
12:15 PM
Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare?
John H. Stone1, Peter A. Merkel2, Philip Seo3, Robert F. Spiera4, Carol A. Langford5, Gary S. Hoffman5, Cees GM Kallenberg6, E. William St. Clair7, Barri J. Fessler8, Nadia Tchao9, Lisa Webber10, Linna Ding11, Lourdes P. Sejismundo12, Kathleen Mieras13, David Ikle14, Deborah J. Phippard9, Brett Jepson14, Alice Lail14, Adam Asare9, Noha Lim9, Mark Mueller15, Paul Brunetta16, Nancy B. Allen17, Fernando Fervenza13, Duvuru Geetha18, Karina Keogh13, Eugene Y. Kissin19, Paul A. Monach19, Tobias Peikert13, Coen Stegeman6, Steven R. Ytterberg13, Ulrich Specks13 and for the RAVE-ITN Research Group20, 1Massachusetts General Hospital, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Johns Hopkins Vasculitis Center, Baltimore, MD, 4Hospital for Special Surgery, New York, NY, 5Cleveland Clinic, Cleveland, OH, 6University Medical Center Groningen, Groningen, Netherlands, 7Duke University Medical Center, Durham, 8University of Alabama at Birmingham, Birmingham, AL, 9Immune Tolerance Network, Bethesda, MD, 10National Institute of Allergy and Infectious Diseases, 11NIAID, Bethesda, MD, 12Johns Hopkins University, Baltimore, MD, 13Mayo Clinic, Rochester, MN, 14Rho, Chapel Hill, NC, 15Food & Drug Administration, Bethesda, MD, 16Genentech, So San Francisco, CA, 17Duke University Medical Center, Durham, NC, 18Johns Hopkins University, York, PA, 19Boston University, Boston, MA, 20Bethesda
See more of: ACR Plenary Sessions

To see other sessions for this day, use the date buttons to the left.